ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2035

Conditions
Diffuse Intrinsic Pontine Gliomas (DIPG)Progressive DIPGRefractory DIPGRecurrent DIPGH3K27-altered High Grade Glioma
Interventions
DRUG

ACT001

PO BID at 875 mg/m2 for 28 days

Trial Locations (18)

2031

NOT_YET_RECRUITING

Sydney Children's Hospital, Randwick

3052

NOT_YET_RECRUITING

Royal Children's Hospital, Melbourne

4101

NOT_YET_RECRUITING

Queensland Children's Hospital, South Brisbane

6000

NOT_YET_RECRUITING

Perth Children's Hospital, Perth

19104

NOT_YET_RECRUITING

Children's Hospital of Philidelphia, Philidelphia

20010

NOT_YET_RECRUITING

Children's National Medical Center, Washington D.C.

27708

NOT_YET_RECRUITING

Duke University Medical Center, Durham

30322

NOT_YET_RECRUITING

Emory University/Children's Healthcare of Atlanta, Atlanta

33155

NOT_YET_RECRUITING

Nicklaus Children's Hospital, Miami

43235

RECRUITING

Nationwide Children's Hospital, Columbus

45229

NOT_YET_RECRUITING

Cincinnati Children's Hospital, Cincinnati

48109

NOT_YET_RECRUITING

C.S. Mott Children's Hospital, Ann Arbor

63110

NOT_YET_RECRUITING

St. Louis Children's Hospital, St Louis

69120

NOT_YET_RECRUITING

Hopp Children's Cancer Center at NCT Heidelberg (KiTZ), Heidelberg

77030

NOT_YET_RECRUITING

Texas Children's Hospital, Houston

98105

NOT_YET_RECRUITING

Seattle Children's Hospital, Seattle

M5G1X8

NOT_YET_RECRUITING

The Hospital for Sick Children (SickKids), Toronto

H4A3J1

NOT_YET_RECRUITING

Montreal Children's Hospital, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Accendatech USA Inc.

INDUSTRY

lead

Nationwide Children's Hospital

OTHER